154 related articles for article (PubMed ID: 10561180)
1. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children.
Kremer LC; Tiel-van Buul MM; Ubbink MC; Offringa M; Ottenkamp J; Olmos RV; Voûte PA
J Clin Oncol; 1999 Apr; 17(4):1208. PubMed ID: 10561180
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction.
Valdés Olmos RA; ten Bokkel Huinink WW; ten Hoeve RF; van Tinteren H; Bruning PF; van Vlies B; Hoefnagel CA
Ann Oncol; 1994 Sep; 5(7):617-22. PubMed ID: 7993837
[TBL] [Abstract][Full Text] [Related]
3. High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction.
Valdés Olmos RA; Carrió I; Hoefnagel CA; Estorch M; ten Bokkel Huinink WW; López-Pousa J; Dalesio O
Nucl Med Commun; 2002 Sep; 23(9):871-7. PubMed ID: 12195092
[TBL] [Abstract][Full Text] [Related]
4. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.
Estorch M; Carrió I; Martínez-Duncker D; Berná L; Torres G; Alonso C; Ojeda B
J Clin Oncol; 1993 Jul; 11(7):1264-8. PubMed ID: 8315423
[TBL] [Abstract][Full Text] [Related]
5. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.
Estorch M; Carrió I; Berná L; Martínez-Duncker C; Alonso C; Germá JR; Ojeda B
J Nucl Med; 1990 Dec; 31(12):1965-9. PubMed ID: 2266394
[TBL] [Abstract][Full Text] [Related]
6. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
7. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity.
Carrió I; Estorch M; Berná L; López-Pousa J; Tabernero J; Torres G
J Nucl Med; 1995 Nov; 36(11):2044-9. PubMed ID: 7472595
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity.
Maini CL; Sciuto R; Ferraironi A; Vici P; Tofani A; Festa A; Conti F; Lopez M
J Nucl Cardiol; 1997; 4(6):502-8. PubMed ID: 9456190
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of alcohol-induced myocardial damage detected by indium-111-labeled monoclonal antimyosin antibodies.
Ballester M; Martí V; Carrió I; Obrador D; Moya C; Pons-Lladó G; Bernà L; Lamich R; Aymat MR; Barbanoj M; Guardia J; Carreras F; Udina C; Augé JM; Marrugat J; Permanyer G; Caralps-Riera JM
J Am Coll Cardiol; 1997 Jan; 29(1):160-7. PubMed ID: 8996309
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.
de Matos Neto RP; Petrilli AS; Silva CM; Campos Filho O; Oporto VM; Gomes Lde F; Paiva MG; Carvalho AC; Moisés VA
Arq Bras Cardiol; 2006 Dec; 87(6):763-71. PubMed ID: 17262115
[TBL] [Abstract][Full Text] [Related]
11. Detection of adriamycin cardiotoxicity with indium-111 labeled antimyosin monoclonal antibody imaging.
Yamada T; Matsumori A; Tamaki N; Morishima S; Watanabe Y; Yonekura Y; Endo K; Konishi J; Kawai C
Jpn Circ J; 1991 Apr; 55(4):377-83. PubMed ID: 2046143
[TBL] [Abstract][Full Text] [Related]
12. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
13. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies.
Carrió I; Estorch M; Berná L; Germá JR; Alonso C; Ojeda B; de Andrés L; Lopez-Pousa A; Martinez-Duncker C; Torres G
Eur J Nucl Med; 1991; 18(10):806-12. PubMed ID: 1743203
[TBL] [Abstract][Full Text] [Related]
14. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
15. Myocardial uptake of 111In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Morphological and hemodynamic findings.
Hiroe M; Ohta Y; Fujita N; Nagata M; Toyozaki T; Kusakabe K; Sekiguchi M; Marumo F
Circulation; 1992 Dec; 86(6):1965-72. PubMed ID: 1451268
[TBL] [Abstract][Full Text] [Related]
16. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?
Köseoğlu V; Berberoğlu S; Karademir S; Kismet E; Yurttutan N; Demirkaya E; Sungur M; Alehan D
Turk J Pediatr; 2005; 47(1):17-22. PubMed ID: 15884624
[TBL] [Abstract][Full Text] [Related]
17. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
18. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
[TBL] [Abstract][Full Text] [Related]
19. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy.
Sipola P; Vanninen E; Jantunen E; Nousiainen T; Kiviniemi M; Hartikainen J; Kuittinen T
Nucl Med Commun; 2012 Jan; 33(1):51-9. PubMed ID: 22044862
[TBL] [Abstract][Full Text] [Related]
20. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
